StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a report issued on Friday morning. The firm issued a hold rating on the biotechnology company's stock.
Separately, Northland Securities downgraded shares of Nabriva Therapeutics from an outperform rating to an underperform rating in a research report on Friday, January 6th.
Get Nabriva Therapeutics alerts:Nabriva Therapeutics Stock Performance
Nabriva Therapeutics stock opened at $1.60 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.20 and a quick ratio of 1.40. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $9.73. The company has a fifty day moving average price of $1.71 and a two-hundred day moving average price of $1.94. The company has a market cap of $49.02 million, a PE ratio of -0.08 and a beta of 1.56.
Institutional Trading of Nabriva Therapeutics
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC lifted its position in shares of Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the period. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 0.23% of the company's stock.
About Nabriva Therapeutics
(Get Rating)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Further Reading
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- This Is Why Penny Stock GreenPower Motor Company Is A Win
- Comcast Sum of All Parts is Producing a Cumulative Effect
- The Greenbrier Companies: All Aboard For High-Yield In 2023
- Coty Stock is on the Comeback Trail
- Splunk Stock is an AI-Powered Enterprise SEIM Play
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
